Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

Skyrizi (risankizumab-rzaa) is prescribed for Crohn’s disease and certain other inflammatory conditions. As with other drugs, Skyrizi can cause side effects, such as headache and injection site ...

Several medications now calm painful inflammation in the intestines. Diets free of ultraprocessed foods also help ...

Gov. Wes Moore made lowering drug costs a key campaign promise, making advocates of the law confident that their greatest ...

The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...

The top 10 projected best-selling medications in 2026, including GLP-1 drugs and AbbVie's Skyrizi, have expected global sales reaching up to $31 billiion.

Analysts at GlobalData have predicted that, fuelled by new indications, the two drugs could make peak combined sales of $32 billion by 2020, with Skyrizi accounting for around $20 billion of that ...

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s disease ...

AbbVie’s Skyrizi, a biologic approved for plaque ... the list from 2024 are Pfizer’s COVID-19 vaccine and two cancer medications, Opdivo and Gardasil.